Lisata Therapeutics (NASDAQ:LSTA) Issues Earnings Results, Beats Estimates By $0.14 EPS

Lisata Therapeutics (NASDAQ:LSTA) posted its earnings results on Monday. The company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.14, Zacks reports. During the same period in the prior year, the business posted ($0.50) earnings per share.

Lisata Therapeutics Stock Down 1.0 %

NASDAQ:LSTA traded down $0.03 on Wednesday, hitting $2.91. The stock had a trading volume of 1,627 shares, compared to its average volume of 14,310. The business’s 50-day simple moving average is $3.37 and its two-hundred day simple moving average is $3.09. Lisata Therapeutics has a 52-week low of $1.95 and a 52-week high of $3.83. The stock has a market cap of $24.17 million, a price-to-earnings ratio of -1.17 and a beta of 1.24.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Lisata Therapeutics in a research note on Tuesday.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.